Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality‐of‐life assessments

In a previous phase 2 trial, axitinib was active and well tolerated in patients with advanced thyroid cancer. In this second phase 2 trial, the efficacy and safety of axitinib were evaluated further in this population, and pharmacokinetic/pharmacodynamic relationships and patient‐reported outcomes were assessed.

[1]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Paschke,et al.  Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[4]  R. Motzer,et al.  Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis , 2013, Journal of clinical pharmacology.

[5]  Roger. T. Anderson,et al.  Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. , 2013, Thyroid : official journal of the American Thyroid Association.

[6]  J. Coebergh,et al.  Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: A study from the population-based PROFILES registry , 2013, Acta oncologica.

[7]  M. Schlumberger,et al.  Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma , 2012, Expert review of anticancer therapy.

[8]  Thomas Krause,et al.  Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. , 2012, The Lancet. Oncology.

[9]  M. Kreissl,et al.  An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. , 2012 .

[10]  D. Ramies,et al.  Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). , 2012 .

[11]  A. Jemal,et al.  Cancers with increasing incidence trends in the United States: 1999 through 2008 , 2012, CA: a cancer journal for clinicians.

[12]  A. Hinz,et al.  Quality of life in patients with thyroid cancer compared with the general population. , 2012, Thyroid : official journal of the American Thyroid Association.

[13]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[15]  K. Harrington,et al.  Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. , 2011, European journal of endocrinology.

[16]  M. Ratain,et al.  Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Rini,et al.  Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors , 2011, Clinical Cancer Research.

[18]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[19]  B. Goh,et al.  Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. , 2010, The Lancet. Oncology.

[20]  D. Mankoff,et al.  Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation , 2010, Clinical Cancer Research.

[21]  Guo-Pei Yu,et al.  Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. , 2010, Thyroid : official journal of the American Thyroid Association.

[22]  L. Bastholt,et al.  Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Nathaniel Rothman,et al.  International patterns and trends in thyroid cancer incidence, 1973–2002 , 2009, Cancer Causes & Control.

[24]  Jiachao Liang,et al.  Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[26]  Andrea B Troxel,et al.  Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Urken,et al.  Quality of life after thyroid cancer: An assessment of patient needs and preferences for information and support , 2008, Journal of Cancer Education.

[29]  T. Fojo,et al.  Is there room for improvement in adverse event reporting in the era of targeted therapies? , 2008, Journal of the National Cancer Institute.

[30]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[31]  L. Bresler*,et al.  Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. , 1999, The Journal of endocrinology.

[32]  M. Schott.  Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer , 2009 .

[33]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[34]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.